Genmab | GEN - Current Liabilities



Genmab reported DKK629M in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
Agios Pharmaceuticals USD 70.41M 18.04M Jun/2025
Almirall EUR 298.52M 36.18M Jun/2025
Amarin USD 162.41M 17.54M Mar/2025
Amgen USD 20.48B 2.53B Jun/2025
argenx SE 1.04B 371.99M Jun/2025
AstraZeneca USD 33.54B 4.41B Jun/2025
Bayer EUR 29.78B 1.82B Jun/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Demant DKK 5.79B 301M Jun/2025
Exelixis USD 336.11M 62.99M Jul/2025
Fresenius Medical Care EUR 5.66B 213.7M Jun/2025
Galapagos EUR 402.95M 34.09M Jun/2025
Genmab DKK 629M 127M Jun/2025
GlaxoSmithKline GBP 20.38B 453M Jun/2025
GN Store Nord DKK 7.89B 5M Jun/2025
GRIFOLS EUR 1.99B 180.07M Jun/2025
Hikma Pharmaceutical USD 1.98B 598M Dec/2024
Insmed USD 311.68M 72.45M Jun/2025
Lonza CHF 3.58B 970M Dec/2024
Merck EUR 9.86B 357M Jun/2025
Novartis USD 31.71B 95M Jun/2025
Regeneron Pharmaceuticals USD 3.67B 100.4M Jun/2025
Roche Holding CHF 27.02B 424M Dec/2024
Sanofi 29.06B 3.16B Jun/2025
UCB EUR 3.53B 731M Dec/2024